Southwest Research Institute

Lantern Pharma Inc.

Shawn T Blumberg

Paul W Miguel

Antonio A Menchaca

Daniel A Hinojosa

Gregory J Tobin

Andrey D Malakhov

Christopher Dorsey

Asa Waterman

Varsin A Archer

A synthetic route to scopolamine and/or atropine. In such context, the present invention identifies a method for preparing 6,7-dehydro atropine, which can be converted into either scopolamine and/or atropine, along with a method for converting a protected pyrrole into a tetrachlorobicylic compound, such as benzyl 3-oxo-8-azabicyclo[3.2.1]oct-6-ene-8-carboxylate.

Synthetic route to scopolamine and/or atropine

Purification of bis-quaternary pyridinium oximes (BQPO) which may serve as organophosphorus nerve agent antidotes.

Purification of bis-quaternary pyridinium oximes

The present invention is directed at the synthesis and characterization of recrystallized HI-6 dimethylsulfate (DMS). The method can comprise dissolving HI-6 DMS in an alkyl-based glycol and adding an antisolvent to recrystallize HI-6 DMS or dissolving HI-6 DMS in methanol and adding dimethoxy ethane or dimethyl formamide as the antisolvent to recrystallize HI-6 DMS. The recrystallized HI-6 DMS indicates a resistance to moisture absorption and/or a DSC melting point onset (MP Onset) at least at or above 160.0° C.

Recrystallized HI-6 dimethylsulfate

This invention provides illudin derivatives, intermediates, preparation methods, pharmaceutical compositions and uses thereof. Specific examples include novel synthetic routes to prepare illudin derivatives and an illudin derivative having a positive optical rotation, which has therapeutic value.

Illudin analogs, uses thereof, and methods for synthesizing the same

The present invention relates to a new route to bis-quaternary pyridinium oximes which can be utilized to restore activity of acetylcholinesterase inhibited by combination with organophosphates.

Growing community of inventors

San Antonio, TX, United States of America

Shawn T Blumberg